Geovax Labs, Inc. cash flow statement

In fiscal 2025, Geovax Labs, Inc.'s operations generated −$21.5m of cash; it spent $27,612 on capital projects, leaving free cash flow of −$21.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Geovax Labs, Inc.: cash flow statement, annual
Fiscal year	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−2	−2	−2	−1	−3	−11	−19	−25	−25	−21	−18
Depreciation and amortisation	0	0	0	0	0	0	0	0	0	0	0
Stock-based pay	1	0	0	0	0	0	1	1	1	1	1
Capital spending	—	0	—	0	0	0	0	0	0	0	0
Free cash flow	—	−2	—	−1	−3	−11	−19	−25	−25	−22	−18
Free cash flow after stock pay	—	−2	—	−2	−3	−12	−20	−26	−25	−23	−19
Shares issued	1	1	—	—	—	—	—	—	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Geovax Labs, Inc.: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−9,297	−7,754	−5,966	−4,334	−6,212	−4,962	−3,538	−3,658
Depreciation and amortisation	30	22	17	17	17	18	12	12
Stock-based pay	130	139	293	293	278	252	219	149
Capital spending	21	0	17	11	0	0	0	0
Free cash flow	−9,318	−7,754	−5,983	−4,345	−6,212	−4,962	−3,538	−3,658
Free cash flow after stock pay	−9,448	−7,893	−6,275	−4,638	−6,490	−5,214	−3,757	−3,807

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Geovax Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Geovax Labs, Inc.